MABSWITCH, INC.

Biotech · Private

Switchable affinity ligands for mild-elution purification of lentiviral vectors

Grants
$739K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · SaefCAR: Regulatable CAR-T cells for safe and effective immunotherapy$399,958
Federal grantDepartment of Health and Human Services · Phase I · LentiSAFE Ligands: Mild-Elution Immunoaffinity Ligands for Enrichment and Purification of Lentiviral Vectors$338,997
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3126ThirdLaw Technologies LLC——
3127AVANTYX, LLC——
3128MYRIEL, INC.——
3129MABSWITCH, INC.——
3130KINEA BIO, INC.——
3131nChroma Bio——
3132ATB Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Bispecific Molecule With Tunable Affinity To A Targeted Antigenapplication
  • Bispecific Molecule With Tunable Affinity To A Targeted Antigenapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.